BR9907300A - Inibidores do fator xa oxoaza-heterociclila substituìdos - Google Patents

Inibidores do fator xa oxoaza-heterociclila substituìdos

Info

Publication number
BR9907300A
BR9907300A BR9907300-5A BR9907300A BR9907300A BR 9907300 A BR9907300 A BR 9907300A BR 9907300 A BR9907300 A BR 9907300A BR 9907300 A BR9907300 A BR 9907300A
Authority
BR
Brazil
Prior art keywords
factor
inhibitors
substituted
oxoaza
heterocyclyl
Prior art date
Application number
BR9907300-5A
Other languages
English (en)
Portuguese (pt)
Inventor
William R Ewing
Michael R Becker
Yong Mi Choi-Sledeski
Heinz W Pauls
Wei He
Stephen M Condon
Roderick S Davis
Barbara A Hanney
Alfred P Spada
Christopher J Burns
John Z Jiang
Aiwen Li
Michael R Myers
Wan F Lau
Gregory B Poli
Original Assignee
Aventis Pharm Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharm Prod Inc filed Critical Aventis Pharm Prod Inc
Publication of BR9907300A publication Critical patent/BR9907300A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
BR9907300-5A 1998-01-27 1999-01-27 Inibidores do fator xa oxoaza-heterociclila substituìdos BR9907300A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7270798P 1998-01-27 1998-01-27
PCT/US1999/001682 WO1999037304A1 (en) 1998-01-27 1999-01-27 SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS

Publications (1)

Publication Number Publication Date
BR9907300A true BR9907300A (pt) 2000-10-24

Family

ID=22109280

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9907300-5A BR9907300A (pt) 1998-01-27 1999-01-27 Inibidores do fator xa oxoaza-heterociclila substituìdos

Country Status (25)

Country Link
US (1) US7612075B2 (US07612075-20091103-C00034.png)
EP (1) EP1051176B1 (US07612075-20091103-C00034.png)
JP (1) JP4676613B2 (US07612075-20091103-C00034.png)
KR (1) KR20010034442A (US07612075-20091103-C00034.png)
CN (1) CN1291892A (US07612075-20091103-C00034.png)
AP (1) AP2000001889A0 (US07612075-20091103-C00034.png)
AT (1) ATE346050T1 (US07612075-20091103-C00034.png)
AU (1) AU745425B2 (US07612075-20091103-C00034.png)
BG (1) BG104633A (US07612075-20091103-C00034.png)
BR (1) BR9907300A (US07612075-20091103-C00034.png)
CA (1) CA2319198C (US07612075-20091103-C00034.png)
DE (1) DE69934093T2 (US07612075-20091103-C00034.png)
EA (1) EA200000768A1 (US07612075-20091103-C00034.png)
EE (1) EE200000435A (US07612075-20091103-C00034.png)
HU (1) HUP0101810A3 (US07612075-20091103-C00034.png)
IL (2) IL137517A0 (US07612075-20091103-C00034.png)
IS (1) IS5574A (US07612075-20091103-C00034.png)
NO (1) NO20003808L (US07612075-20091103-C00034.png)
PL (1) PL342243A1 (US07612075-20091103-C00034.png)
SK (1) SK11082000A3 (US07612075-20091103-C00034.png)
TR (1) TR200002182T2 (US07612075-20091103-C00034.png)
UA (1) UA59433C2 (US07612075-20091103-C00034.png)
WO (1) WO1999037304A1 (US07612075-20091103-C00034.png)
YU (1) YU47600A (US07612075-20091103-C00034.png)
ZA (1) ZA99607B (US07612075-20091103-C00034.png)

Families Citing this family (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL135180A0 (en) 1997-09-30 2001-05-20 Daiichi Seiyaku Co Sulfonyl derivatives
CA2317017A1 (en) * 1998-02-05 1999-08-12 Takeda Chemical Industries, Ltd. Sulfonamide derivatives, their production and use
US7517884B2 (en) 1998-03-30 2009-04-14 Kalypsys Inc. Sulfonyl-substituted bicyclic compounds as modulators of PPAR
CA2340100A1 (en) * 1998-08-11 2000-02-24 Daiichi Pharmaceutical Co., Ltd. Novel sulfonyl derivatives
JP2003529531A (ja) * 1998-11-25 2003-10-07 アヴェンティス ファーマシューティカルズ インコーポレイテッド 置換オキソアザへテロシクリルXa因子阻害剤
CA2348740A1 (en) * 1998-12-23 2000-07-06 Ruth R. Wexler Thrombin or factor xa inhibitors
DE60027718T2 (de) 1999-06-22 2007-05-16 Takeda Pharmaceutical Co. Ltd. Acylhydrazinderivate, verfahren zu ihrer herstellung und ihre verwendung
AU773227B2 (en) * 1999-07-28 2004-05-20 Aventis Pharmaceuticals Inc. Substituted oxoazaheterocyclyl compounds
SE9902987D0 (sv) 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
JP2001294572A (ja) * 2000-02-09 2001-10-23 Dai Ichi Seiyaku Co Ltd 新規スルホニル誘導体
DE10012732A1 (de) 2000-03-18 2001-09-20 Aventis Behring Gmbh Thrombin-Zubereitungen und Verfahren zu ihrer Herstellung
AR030357A1 (es) * 2000-08-18 2003-08-20 Lundbeck & Co As H Derivados 4 -, 5 -, 6 - y 7-indol
JP2004509958A (ja) * 2000-09-29 2004-04-02 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 第Xa因子のインヒビターとしてのピペラジン−2−オンアミド
DE60116655T2 (de) 2000-11-08 2006-11-16 Takeda Pharmaceutical Co. Ltd. Carbamatderivate, verfahren zu deren herstellung und deren verwendung
DE10105989A1 (de) 2001-02-09 2002-08-14 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
GB0104050D0 (en) 2001-02-19 2001-04-04 Astrazeneca Ab Chemical compounds
GB0107228D0 (en) 2001-03-22 2001-05-16 Astrazeneca Ab Chemical compounds
AU2002307416B2 (en) 2001-04-18 2005-08-11 Euro-Celtique S.A. Nociceptin analogs
GB0112836D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0114005D0 (en) 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
GB0114004D0 (en) 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
DE10129725A1 (de) 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
ES2258642T3 (es) 2001-07-02 2006-09-01 Astrazeneca Ab Derivados de piperidina utiles como moduladores de la actividad del receptor de quimiocina.
DE10134482A1 (de) 2001-07-16 2003-01-30 Bayer Ag Substituierte Isoindole und ihre Verwendung
DE10137163A1 (de) 2001-07-30 2003-02-13 Bayer Ag Substituierte Isoindole und ihre Verwendung
GB0120461D0 (en) 2001-08-22 2001-10-17 Astrazeneca Ab Novel compounds
WO2003017939A2 (en) 2001-08-24 2003-03-06 Yale University Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment
GB0122503D0 (en) 2001-09-18 2001-11-07 Astrazeneca Ab Chemical compounds
DE10155727A1 (de) * 2001-11-13 2003-05-28 Morphochem Ag Serin Protease Inhibitoren
SE0103818D0 (sv) 2001-11-15 2001-11-15 Astrazeneca Ab Chemical compounds
EP1314733A1 (en) 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
GB0130677D0 (en) 2001-12-21 2002-02-06 Glaxo Group Ltd Medicaments and novel compounds
WO2003066595A2 (en) 2002-02-01 2003-08-14 Euro-Celtique S.A. 2 - piperazine - pyridines useful for treating pain
US7482365B2 (en) 2002-02-08 2009-01-27 Glaxo Group Limited Piperidylcarboxamide derivatives and their use in the treatment of tachykinin-mediated diseases
GB0203020D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
SE0200844D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
SE0200843D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
AU2003231359B2 (en) 2002-04-16 2009-04-30 Teijin Limited Piperidine derivatives having CCR3 antagonism
JP4429738B2 (ja) 2002-04-25 2010-03-10 帝人株式会社 Ccr3拮抗作用を有する4,4−二置換ピペリジン誘導体
KR20030084444A (ko) * 2002-04-26 2003-11-01 주식회사 파나진 Pna 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법
US6864261B2 (en) 2002-05-02 2005-03-08 Euro-Celtique S.A. Therapeutic agents useful for treating pain
TW200409637A (en) 2002-06-26 2004-06-16 Glaxo Group Ltd Compounds
WO2004050637A2 (en) 2002-12-03 2004-06-17 Axys Pharmaceuticals, Inc. 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors
US7429581B2 (en) 2002-12-23 2008-09-30 Sanofi-Aventis Deutschland Gmbh Pyrazole-derivatives as factor Xa inhibitors
US7582635B2 (en) 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
DE10300111A1 (de) 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
TW200508224A (en) 2003-02-12 2005-03-01 Bristol Myers Squibb Co Cyclic derivatives as modulators of chemokine receptor activity
SE0300957D0 (sv) 2003-04-01 2003-04-01 Astrazeneca Ab Chemical compounds
GB0314738D0 (en) 2003-06-24 2003-07-30 Glaxo Group Ltd Novel compounds
WO2005007641A1 (en) * 2003-07-03 2005-01-27 Euro-Celtique S.A. 2-pyridine alkyne derivatives useful for treating pain
KR100954415B1 (ko) 2003-07-24 2010-04-26 유로-셀띠끄 소시에떼 아노님 피페리딘 화합물 및 그들을 포함하는 약학적 조성물
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
CA2545261C (en) 2003-11-17 2013-07-23 Boehringer Ingelheim International Gmbh Piperidine-substituted indoles- or heteroderivatives thereof
DE10355461A1 (de) 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
EP1722792A1 (de) * 2004-03-03 2006-11-22 Boehringer Ingelheim International GmbH Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
US7269708B2 (en) * 2004-04-20 2007-09-11 Rambus Inc. Memory controller for non-homogenous memory system
GB0414093D0 (en) 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
ATE518858T1 (de) * 2004-09-03 2011-08-15 Yuhan Corp Pyrroloä3,2-cüpyridinderivate und herstellungsverfahren dafür
GB0420831D0 (en) 2004-09-17 2004-10-20 Glaxo Group Ltd Novel compounds
TW200630337A (en) 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
MX2007005205A (es) 2004-10-29 2007-05-11 Kalypsys Inc Compuestos biciclicos sulfonilo-sustituidos como moduladores de receptores activados por el proliferador de la peroxisoma.
EP1685841A1 (en) 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention and treatment of thromboembolic disorders
TWI385164B (zh) 2005-02-17 2013-02-11 Astellas Pharma Inc Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate derivatives (II)
US7918848B2 (en) 2005-03-25 2011-04-05 Maquet Cardiovascular, Llc Tissue welding and cutting apparatus and method
US8197472B2 (en) 2005-03-25 2012-06-12 Maquet Cardiovascular, Llc Tissue welding and cutting apparatus and method
JP5080450B2 (ja) 2005-04-30 2012-11-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規なピペリジン置換インドール
US20060281768A1 (en) * 2005-06-10 2006-12-14 Gaul Michael D Thienopyrimidine and thienopyridine kinase modulators
WO2007011293A1 (en) 2005-07-21 2007-01-25 Astrazeneca Ab Novel piperidine derivatives
US7544685B2 (en) 2005-08-17 2009-06-09 H. Lundbeck A/S 2,3-dihydroindole compounds
WO2007029629A1 (ja) 2005-09-06 2007-03-15 Shionogi & Co., Ltd. Pgd2受容体アンタゴニスト活性を有するインドールカルボン酸誘導体
DE102005045518A1 (de) 2005-09-23 2007-03-29 Bayer Healthcare Ag 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
WO2007037187A1 (ja) 2005-09-27 2007-04-05 Shionogi & Co., Ltd. Pgd2受容体アンタゴニスト活性を有するスルホンアミド誘導体
DE102005047561A1 (de) 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
PL1934208T3 (pl) 2005-10-04 2011-09-30 Bayer Ip Gmbh Nowa polimorficzna postać 5-chloro-N-({ (5S)-2-okso-3-[4-( 3-okso-4-morfolinylo)-fenylo]-1,3-oksazolidyn-5-ylo}-metylo)-2-tiofenokarboksamidu
US7863276B2 (en) 2005-10-25 2011-01-04 Kalypsys, Inc Salts of modulators of PPAR and methods of treating metabolic disorders
WO2007080430A1 (en) * 2006-01-16 2007-07-19 Generics [Uk] Limited Novel process
WO2007110449A1 (en) * 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
US8937181B2 (en) * 2006-04-13 2015-01-20 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
TW200815353A (en) * 2006-04-13 2008-04-01 Euro Celtique Sa Benzenesulfonamide compounds and their use
US8017612B2 (en) 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor
US7629351B2 (en) 2006-07-28 2009-12-08 Bristol-Myers Squibb Company N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino) pyrrolidin-1-yl)cyclohexyl)acetamide and other modulators of chemokine receptor activity, crystalline forms and process
US7671062B2 (en) 2006-07-28 2010-03-02 Bristol-Myers Squibb Company Modulators of chemokine receptor activity, crystalline forms and process
US7687508B2 (en) 2006-07-28 2010-03-30 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
EP2079739A2 (en) * 2006-10-04 2009-07-22 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
CA2667547C (en) 2006-10-27 2014-07-29 Boehringer Ingelheim International Gmbh Piperidyl-propane-thiol ccr3 modulators
WO2008091863A1 (en) 2007-01-23 2008-07-31 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis
SI2069324T1 (sl) * 2007-03-20 2013-10-30 Curis, Inc. Kondenzirani aminopiridini kot HSP90-inhibitorji
US8173645B2 (en) * 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
US8399486B2 (en) 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
ES2453947T3 (es) * 2007-04-27 2014-04-09 Purdue Pharma Lp Antagonistas de TRPV1 y usos de los mismos
AU2008246202B2 (en) 2007-04-27 2011-12-01 Purdue Pharma L.P. Therapeutic agents useful for treating pain
KR20100033544A (ko) * 2007-07-19 2010-03-30 에프. 호프만-라 로슈 아게 신규한 헤테로사이클일 화합물 및 이의 케모카인 길항제로서의 용도
EP2195293B1 (en) 2007-08-22 2013-10-16 AstraZeneca AB Cycloptopyl amide derivatives
US8765736B2 (en) * 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
EP2199282A4 (en) * 2007-10-10 2011-04-27 Takeda Pharmaceutical AMIDE COMPOUND
JP2011500767A (ja) 2007-10-26 2011-01-06 グラクソ グループ リミテッド P2x7モジュレータとしての4−ベンゾイル−1−置換ピペラジン−2−オン誘導体
KR100967171B1 (ko) 2007-12-26 2010-07-05 재단법인서울대학교산학협력재단 Δ5-2-옥소피페라진 유도체 및 그의 고체상 합성 방법
PT2264009T (pt) 2008-03-12 2019-04-29 Ube Industries Composto do ácido piridilaminoacético
TW200944526A (en) 2008-04-22 2009-11-01 Vitae Pharmaceuticals Inc Carbamate and urea inhibitors of 11β-hydroxysteroid dehydrogenase 1
US9402680B2 (en) 2008-05-27 2016-08-02 Maquet Cardiovasular, Llc Surgical instrument and method
EP3175806B1 (en) 2008-05-27 2018-10-17 Maquet Cardiovascular LLC Surgical instrument
US9968396B2 (en) 2008-05-27 2018-05-15 Maquet Cardiovascular Llc Surgical instrument and method
GB0813142D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
GB0813144D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
US8703962B2 (en) * 2008-10-24 2014-04-22 Purdue Pharma L.P. Monocyclic compounds and their use as TRPV1 ligands
US8759362B2 (en) * 2008-10-24 2014-06-24 Purdue Pharma L.P. Bicycloheteroaryl compounds and their use as TRPV1 ligands
WO2010065674A1 (en) 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
KR101370130B1 (ko) 2008-12-23 2014-03-05 에프. 호프만-라 로슈 아게 P2x7 조절제로서의 디히드로피리돈 아미드
EP2385939A1 (en) 2008-12-23 2011-11-16 F. Hoffmann-La Roche AG Dihydropyridone amides as p2x7 modulators
US8153808B2 (en) 2008-12-23 2012-04-10 Roche Palo Alto Llc Dihydropyridone amides as P2X7 modulators
SG172385A1 (en) 2008-12-23 2011-08-29 Hoffmann La Roche Dihydropyridone amides as p2x7 modulators
CN102264701A (zh) 2008-12-23 2011-11-30 霍夫曼-拉罗奇有限公司 作为p2x7调节剂的二氢吡啶酮脲
TW201039825A (en) 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
KR101681347B1 (ko) 2009-03-30 2016-11-30 우베 고산 가부시키가이샤 녹내장의 치료 또는 예방을 위한 의약 조성물
TW201044234A (en) * 2009-06-08 2010-12-16 Chunghwa Picture Tubes Ltd Method of scanning touch panel
US9955858B2 (en) 2009-08-21 2018-05-01 Maquet Cardiovascular Llc Surgical instrument and method for use
US8383812B2 (en) 2009-10-13 2013-02-26 Bristol-Myers Squibb Company N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes
WO2011050284A1 (en) * 2009-10-23 2011-04-28 Glaxosmithkline Llc Pyrazolylpyridine antiviral agents
EP2493874A1 (en) 2009-10-30 2012-09-05 Glaxo Group Limited Novel crystalline forms of (3r,6r) -3- (2, 3 -dihydro- 1h- inden- 2 -yl) - 1 - [ (1r) - 1 - (2, 6 - dimethyl - 3 - pyridinyl) - 2 - (4 -morpholinyl) -2-oxoethyl]-6- [(1s) - 1 -methylpropyl]-2,5- piperazinedione
KR20130002316A (ko) 2010-02-18 2013-01-07 아스트라제네카 아베 시클로프로필 벤즈아미드 유도체의 신규 결정질 형태
WO2011162409A1 (en) 2010-06-22 2011-12-29 Shionogi & Co., Ltd. Compounds having trpv1 antagonistic activity and uses thereof
US8609672B2 (en) 2010-08-27 2013-12-17 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
CN103261205B (zh) * 2010-11-12 2015-08-19 姚雪彪 动点马达蛋白cenp-e小分子抑制剂syntelin及其应用
EP2642998B1 (en) 2010-11-24 2020-09-16 The Trustees of Columbia University in the City of New York A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease
PE20141531A1 (es) 2011-06-22 2014-10-23 Purdue Pharma Lp Antagonistas de trpv1 que incluyen sustituyentes dihidroxi y sus usos
AU2012293417A1 (en) 2011-08-10 2013-05-02 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
US9333202B2 (en) 2012-05-01 2016-05-10 The Trustees Of Columbia University In The City Of New York Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease
DK2968304T3 (en) 2013-03-14 2019-01-28 Univ Columbia 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE.
US9944644B2 (en) 2013-03-14 2018-04-17 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles their preparation and use
US9938291B2 (en) 2013-03-14 2018-04-10 The Trustess Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
US9637450B2 (en) 2013-03-14 2017-05-02 The Trustees Of Columbia University In The City Of New York Octahydrocyclopentapyrroles, their preparation and use
EP2824806B1 (en) * 2013-07-09 2020-03-04 ABB Schweiz AG Ship's propulsion unit
KR102429220B1 (ko) 2014-04-30 2022-08-04 더 트러스티이스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 치환 4-페닐피페리딘, 그 제조 및 사용
US9878989B2 (en) 2015-06-26 2018-01-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
CN106349228B (zh) 2015-07-17 2019-07-09 广东东阳光药业有限公司 取代的喹唑啉酮类化合物及其制备方法和用途
EP3366679B1 (en) 2015-10-20 2021-03-24 Takeda Pharmaceutical Company Limited Heterocyclic compound
AU2016348549B2 (en) 2015-11-02 2020-07-23 Janssen Pharmaceutica Nv [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compound
TWI764950B (zh) 2016-11-02 2022-05-21 比利時商健生藥品公司 Pde2抑制劑
CN109890824B (zh) 2016-11-02 2022-05-24 詹森药业有限公司 作为pde2抑制剂的[1,2,4]三唑并[1,5-a]嘧啶化合物
ES2855032T3 (es) 2016-11-02 2021-09-23 Janssen Pharmaceutica Nv Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de PDE2
WO2018194181A1 (en) 2017-04-18 2018-10-25 Takeda Pharmaceutical Company Limited Heterocyclic compounds useful as modulators of acetylcholine receptors
CN116606271B (zh) * 2023-07-21 2023-09-29 北京百力格生物科技有限公司 一种3,6-二氯偏苯三酸酐的合成方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2877227A (en) * 1959-03-10 Chichi
GB808046A (en) * 1955-12-13 1959-01-28 Roche Products Ltd Novel substituted pyridone-acetic acid derivatives and process for the manufacture thereof
US3935214A (en) * 1968-07-26 1976-01-27 Donau-Pharmazie Gesellschaft M.B.H. 2-or 3 keto-3-or-2-phenyl-1,4-disubstituted piperazines
JPS49110680A (US07612075-20091103-C00034.png) * 1973-03-12 1974-10-22
JPS5793962A (en) * 1980-12-01 1982-06-11 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
IL92011A0 (en) * 1988-10-19 1990-07-12 Abbott Lab Heterocyclic peptide renin inhibitors
US5120718A (en) * 1991-06-13 1992-06-09 Abbott Laboratories Candida acid protease inhibiting compounds
TW394760B (en) * 1993-09-07 2000-06-21 Hoffmann La Roche Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same
IL115420A0 (en) 1994-09-26 1995-12-31 Zeneca Ltd Aminoheterocyclic derivatives
EP0805149A4 (en) 1994-12-01 1998-03-11 Toyama Chemical Co Ltd NEW 2,3-DICETOPIPERAZINE DERIVATIVE OR SALT THEREOF
GB9508622D0 (en) 1995-04-28 1995-06-14 Pfizer Ltd Therapeutic agants
US5612353A (en) * 1995-06-07 1997-03-18 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds
GB9516709D0 (en) 1995-08-15 1995-10-18 Zeneca Ltd Medicament
GB9602166D0 (en) 1996-02-02 1996-04-03 Zeneca Ltd Aminoheterocyclic derivatives
GB9602294D0 (en) 1996-02-05 1996-04-03 Zeneca Ltd Heterocyclic compounds
EP0897303A1 (en) * 1996-04-03 1999-02-24 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU2733997A (en) * 1996-04-17 1997-11-07 Du Pont Pharmaceuticals Company N-(amidinophenyl)-n'-(subst.)-3h-2,4-benzodiazepin-3-one derivatives as factor xa inhibitors
US6093718A (en) 1996-08-14 2000-07-25 Zeneca Limited Substituted pyrimidine derivatives and their pharmaceutical use
AU4172397A (en) * 1996-09-06 1998-03-26 Biochem Pharma Inc. Lactam inhibitors of thrombin
UA56197C2 (uk) 1996-11-08 2003-05-15 Зенека Лімітед Гетероциклічні похідні
WO1998046626A1 (en) * 1997-04-14 1998-10-22 Cor Therapeutics, Inc. SELECTIVE FACTOR Xa INHIBITORS
US6369063B1 (en) 1997-04-14 2002-04-09 Cor Therapeutics, Inc. Selective factor Xa inhibitors
CA2285335A1 (en) * 1997-04-14 1998-10-22 Cor Therapeutics, Inc. Selective factor xa inhibitors
CA2285705A1 (en) 1997-04-14 1998-10-22 Cor Therapeutics, Inc. Selective factor xa inhibitors
WO1998054164A1 (en) 1997-05-30 1998-12-03 Takeda Chemical Industries, Ltd. Sulfonamide derivatives, their production and use
GB9715892D0 (en) * 1997-07-29 1997-10-01 Zeneca Ltd Heterocyclic compounds
GB9715894D0 (en) 1997-07-29 1997-10-01 Zeneca Ltd Heterocyclic derivatives
GB9715895D0 (en) 1997-07-29 1997-10-01 Zeneca Ltd Heterocyclic compounds
IL135180A0 (en) 1997-09-30 2001-05-20 Daiichi Seiyaku Co Sulfonyl derivatives
EP1048652A4 (en) * 1997-12-26 2001-05-09 Mochida Pharm Co Ltd AROMATIC COMPOUNDS WITH A CYCLIC AMINO GROUP OR THEIR SALTS
CA2317017A1 (en) * 1998-02-05 1999-08-12 Takeda Chemical Industries, Ltd. Sulfonamide derivatives, their production and use
JP2000204081A (ja) * 1998-02-05 2000-07-25 Takeda Chem Ind Ltd スルホンアミド誘導体、その製造法及び用途
WO1999046267A1 (en) * 1998-03-12 1999-09-16 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (ptpases)
DE19835950A1 (de) * 1998-08-08 2000-02-10 Merck Patent Gmbh Piperazinonderivate

Also Published As

Publication number Publication date
IL137517A (en) 2006-12-10
US20040102450A1 (en) 2004-05-27
SK11082000A3 (sk) 2001-01-18
EE200000435A (et) 2002-02-15
EP1051176B1 (en) 2006-11-22
KR20010034442A (ko) 2001-04-25
EP1051176A4 (en) 2002-06-12
JP2002501024A (ja) 2002-01-15
CA2319198A1 (en) 1999-07-29
DE69934093T2 (de) 2007-06-21
PL342243A1 (en) 2001-06-04
IL137517A0 (en) 2001-07-24
UA59433C2 (uk) 2003-09-15
HUP0101810A3 (en) 2002-05-28
US7612075B2 (en) 2009-11-03
HUP0101810A2 (hu) 2002-04-29
ZA99607B (en) 1999-07-27
CN1291892A (zh) 2001-04-18
NO20003808L (no) 2000-09-26
EA200000768A1 (ru) 2001-06-25
AU2653399A (en) 1999-08-09
EP1051176A1 (en) 2000-11-15
BG104633A (bg) 2001-03-30
JP4676613B2 (ja) 2011-04-27
WO1999037304A1 (en) 1999-07-29
AU745425B2 (en) 2002-03-21
ATE346050T1 (de) 2006-12-15
NO20003808D0 (no) 2000-07-25
AP2000001889A0 (en) 2000-09-30
TR200002182T2 (tr) 2000-12-21
YU47600A (sh) 2002-09-19
CA2319198C (en) 2011-02-22
DE69934093D1 (de) 2007-01-04
IS5574A (is) 2000-07-25

Similar Documents

Publication Publication Date Title
BR9907300A (pt) Inibidores do fator xa oxoaza-heterociclila substituìdos
ATE297203T1 (de) Antithrombotische mitteln
ATE272633T1 (de) Aromatische amiden
DE69831868D1 (en) Antithrombosemittel
BR0010555A (pt) Inibidores de neuraminidases
BR0212510A (pt) Inibidor de histona desacetilase, composto e composição
SE9203825D0 (sv) Dual inhibitors of no synthase and cyclooxygenase, process for their preparation and therapeutical compositions containing them
ATE273305T1 (de) Thrombin-inhibitoren
DE69931393D1 (de) Antithrombotische amide
BR9804437A (pt) Compostos para a osteoporose
UY25322A1 (es) Compuestos de tiourea y benzamida,composiciones y metodos para tratar y prevenir enfermedades inflamatorias y aterosclerosis
NO991494D0 (no) <beta>-sulfonylhydroksaminsyrer som matriksmetalloproteinaseinhibitorer
BR9915727A (pt) ésteres derivados de compostos de fenil-ciclohexila substituìdos
DK1436257T3 (da) Oxim-analogica af 1-alpha, 25-dihydroxy-vitamin-D3 med ringe kalcemisk virkning
CO5261493A1 (es) Procedimiento y compuestos para la inhibicion de la mrp1
BR0100234A (pt) Compostos de piperidina-4-sulfonamida, processo para a sua preparação e composições farmacêuticas contendo os mesmos
ATE297903T1 (de) Substituierte phenyluracile
DE60114640D1 (en) Antithrombosemittel
BR9909870A (pt) Pirrolidinas como inibidores de neuraminidases
ES2189080T3 (es) Derivados de creatina para el asma.
MY129094A (en) Condensed polycyclic compounds
BR0211425A (pt) Método para a preparação de compostos, e, uso de uma composição
BR9810481A (pt) Processo para preparação de 1h-indol-3-glioxamidas 4-substituìdas.
BR0111767A (pt) Composições analgésicas e anti-inflamatórias contendo inibidores de cox-2, seu uso e método para potencializar um composto analgésico
BR0116721A (pt) Processo para a preparação de (±)-trans-4-p-fluorofenil-3-hidroximetil-1-metilpiperi dina

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6O, 7O E 8O ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1913 DE 04/09/2007.